… Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2
diabetes: a randomized, double-blind crossover trial. Diabetes Care 2021;44:1334–1343. [PMC …

… (SGLT2) inhibitor dapagliflozin reduced the risk of hospital admission for worsening heart
failure, … and at much higher cardiovascular risk than patients in the prior SGLT2 inhibitor trials. …

… SGLT2 inhibition in patients with heart failure were provided by the Effect of Sotagliflozin on
Cardiovascular Events in Patients … SGLT2 inhibitor (in this case dapagliflozin) on mortality in …

… Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization
across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2018;…

… the SGLT2 inhibitor dapagliflozin on LV diastolic functional parameters of T2DM patients with
… and 6 months after administration of dapagliflozin. LV diastolic function was defined as the …

… the SGLT2 inhibitor dapagliflozin was added to a guideline-directed therapy. This marks a
dramatic evolution of this particular agent (feasibly extensible to others) from being initially a …

… Here, we discuss the use of SGLT2 inhibitors for heart failure with a focus on dapagliflozin …
This may explain how SGLT2 inhibitor-mediated diuresis improves heart failure outcomes also…

… SGLT2 inhibitor trials and shows clinically relevant, largely cardiometabolic, benefits of
dapagliflozin in patients … Importantly, patients with any degree of globally or regionally impaired …

… type of SGLT2 inhibitor used (empagliflozin, dapagliflozin, … that some patients with present
heart failure were undiagnosed. … most common SGLT2 inhibitors empagliflozin, dapagliflozin, …

… in cardiovascular disease or kidney disease with several commercial organisations. RTG
has consulting agreements with AstraZeneca, Bayer, Sanofi–Genzyme, and Mundi Pharma; all …